{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:59:17Z","timestamp":1791291557409,"version":"4.3.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T00:00:00Z","timestamp":1416873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ejca.2014.11.015","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T13:25:57Z","timestamp":1418995557000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct00805194","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Silvia","family":"Novello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Mellemgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"von Pawel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gottfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Barrueco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Gaschler-Markefski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Griebsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.11.015_b0005","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-small Cell Lung Cancer, version 2. In; 2014."},{"issue":"36","key":"10.1016\/j.ejca.2014.11.015_b0010","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1200\/JCO.2010.28.8126","article-title":"The evolving role of histology in the management of advanced non-small-cell lung cancer","volume":"28","author":"Langer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2014.11.015_b0015","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.11.015_b0020","unstructured":"Pfizer Inc., Xalkori (crizotinib) prescribing information. In; 2013."},{"key":"10.1016\/j.ejca.2014.11.015_b0025","unstructured":"AstraZeneca Ltd., Iressa (gefitinib) Summary of Product Characteristics. In; 2013."},{"key":"10.1016\/j.ejca.2014.11.015_b0030","unstructured":"Novartis Pharmaceuticals Corporation. ZYKADIA (ceritinib) prescribing information. In; 2014."},{"key":"10.1016\/j.ejca.2014.11.015_b0035","unstructured":"Boehringer Ingelheim Limited. Giotrif (afatinib) Summary of Product Characteristics. In; 2014."},{"issue":"9","key":"10.1016\/j.ejca.2014.11.015_b0040","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2014.11.015_b0045","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.11.015_b0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2014.11.015_b0055","unstructured":"Roche Products Limited. Tarceva (erlotinib) Summary of Product Characterisitics. In; 2014."},{"issue":"6801","key":"10.1016\/j.ejca.2014.11.015_b0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2014.11.015_b0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14728214.11.4.635","article-title":"Therapeutic options to target angiogenesis in human malignancies","volume":"11","author":"Herbst","year":"2006","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2014.11.015_b0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2012.02.004","article-title":"Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions","volume":"84","author":"Ellis","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.ejca.2014.11.015_b0075","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2014.11.015_b0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2014.11.015_b0085","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11136-012-0229-0","article-title":"The impact of second-line agents on patients\u2019 health-related quality of life in the treatment for non-small cell lung cancer: a systematic review","volume":"22","author":"Ganguli","year":"2013","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.ejca.2014.11.015_b0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2354.2012.01346.x","article-title":"Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data","volume":"21","author":"Larsson","year":"2012","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"8","key":"10.1016\/j.ejca.2014.11.015_b0095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1634\/theoncologist.2013-0096","article-title":"Second-Line Therapy for Advanced NSCLC","volume":"18","author":"Weiss","year":"2013","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejca.2014.11.015_b0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2014.11.015_b0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.11.015_b0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.ejca.2014.11.015_b0115","series-title":"EQ-5D value sets: inventory, comparative review and user guide","author":"Szende","year":"2007"},{"key":"10.1016\/j.ejca.2014.11.015_b0120","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"issue":"1","key":"10.1016\/j.ejca.2014.11.015_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.11.015_b0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914011393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914011393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T21:56:18Z","timestamp":1537998978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914011393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0959804914011393"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.11.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}